To meet the EU MDR deadline, manufacturers urged to automate, implement, audit and accelerate

A research report from RWS highlights the impact of COVID-19 on medical device manufacturers, and their readiness to meet the European Union’s (EU) Medical Device regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) deadline.

The research, involving leading medical device organisations operating in Europe, looks at how the pandemic has affected their preparations to meet the 26 May 2021 deadline for the EU MDR, and EU IVDR deadline of 26 May 2022. 

The research paints an optimistic picture: almost three-quarters (70%) of organisations are positive about meeting the MDR deadline, and 69% remain positive about meeting the IVDR deadline in 2022. 

Research highlights:

“While it’s a positive sign that organisations feel optimistic about meeting their MDR and IVDR commitments, there’s clearly a lot of work to do post-pandemic,” explains Jon Hart, President of RWS Regulated Industries.

“The decisions that medical manufacturing organisations make now won’t just affect their ability to comply with these two regulations, they will also play a continuing role in how quickly and effectively they can meet compliance standards in years to come. Introducing automation into the content management and translation process is a good first step, but a more visionary end-to-end solution that spans the manufacturing organisation and the supply chain will better prepare organisations for the inevitable introduction of future regulations,” added Hart.

Meeting the May deadline

Based on the survey results, organisations are advised to explore the following approaches to meet short and long-term commitments:

Back to topbutton